Abstract: This study investigated the preoperative independent risk factors associated with survival and recurrence for patients with hepatocellular carcinoma (HCC) who underwent hepatic resection. In total, 384 consecutive patients who underwent curative hepatic resection for single primary HCC were studied. Predictive factors associated with 1-, 3-, and 5-year survival and recurrence-free survival (RFS) were assessed using a univariate log-rank test and multivariate Cox proportional hazards regression model.

Gamma-glutamyl transferase (GGT) > 100 U/L was identified as a preoperative independent risk factor affecting 1-, 3-, and 5-year survival whereas GGT > 50 U/L and indocyanine green retention 15 min (ICG-R15) > 10% were identified as preoperative independent risk factors affecting 1-, 3-, and 5-year RFS. The 384 patients studied had a 1-, 3-, and 5-year RFS rate of 72.8%, 43.3%, and 27%, respectively. Patients with GGT > 50 U/L had a 1-, 3-, and 5-year RFS rate of 72.8%, 43.3%, and 27%, respectively. Patients with GGT ≤ 50 U/L (P < 0.05). Patients with GGT > 50 U/L and ICG-R15 > 10% had a 1-, 3-, and 5-year RFS rate of 64.5%, 36.0%, and 21.7%. These patients had lower survival rates than did patients with GGT ≤ 50 U/L (P < 0.05). Patients with GGT > 50 U/L and ICG-R15 > 10% had a 1-, 3-, and 5-year RFS rate of 62.4%, 29.5%, and 14.1%, respectively. These patients had lower survival rates than did patients in the other 2 groups with different levels of GGT and ICG (P < 0.05, respectively).

Combined information in the form of high levels of GGT and ICG-R15 is a preoperative predictor that warrants full attention when evaluating tumor recurrence postoperatively.

(Medicine 94(21):e810)

INTRODUCTION

Hepatocellular carcinoma (HCC) is the second leading cause of cancer deaths worldwide, with an estimated global incidence of 782,000 new cases and nearly 746,000 deaths in 2012.1 In the present era of using hepatic resection for HCC, although improved diagnostic procedures, surgical techniques, and perioperative management have contributed to better outcomes,2–4 the high rate of recurrence after hepatic resection is a problem that impacts patient prognosis, with a cumulative rate of recurrence of 50% and 60% at 3 years and 60% and 80% at 5 years.5–12 Thus, the challenge for surgeons is how to predict recurrence and take interventional measures early on.

To date, certain characteristics of the prognosis of HCC have been investigated, and aspects such as microvascular invasion (MVI), poor differentiation, and tumor size have been identified as significant risk factors affecting prognosis after hepatic resection.13–16 Recently, numerous studies of different subgroups of patients, such as patients with hepatitis B virus (HBV)-related HCC, noncirrhotic HCC, or multinodular tumors, have focused on factors that predict postoperative survival and recurrence in patients with HCC.17–21 However, the characteristics of HCC and/or the patient’s condition varied in those studies, so clinically and biologically significant predictors of tumor recurrence postoperatively are still unclear. In addition, evaluating predictive factors for recurrence of HCC is difficult given patients with multinodular tumors. Thus, the present study investigated independent prognostic risk factors associated with survival and recurrence in patients with single primary HCC with the specific aim of identifying preoperative predictors of tumor recurrence postoperatively.

METHODS

Subjects and Follow-Up

Subjects consisted of 384 consecutive patients who underwent curative hepatic resection for single primary HCC from 1997 to 2007 at the University of Tokyo Hospital, Tokyo, Japan, and this study was approved by the Institutional Review Boards of the University of Tokyo. For specimen of all cases, the
surgical margins were negative. All patients were regularly screened for recurrence through monitoring of HCC-specific tumor markers of alpha-fetoprotein (AFP) and des-gamma-carboxy-prothrombin (DCP) every 1 to 2 months, ultrasonography every 2 months, and dynamic computed tomography every 4 months, as previously reported. There are no cases who died within 1 month after surgery.

Recurrence was defined as the appearance of a new lesion with radiologic features consistent with HCC and was confirmed using at least 2 imaging modalities. Intrahepatic metastasis was identified according to the Liver Cancer Study Group of Japan: General Rules for the Clinical and Pathological Study of Primary Liver Cancer. The present study defined 1-, 3-, and 5-year recurrence-free survival (RFS) as the interval from surgery to the date of diagnosis of the first recurrence or a 5-year recurrence-free survival (RFS) as the interval from surgery to the date of diagnosis of the first recurrence or a follow-up examination during the period in question, and 1-, 3-, and 5-year survival was calculated based on the time from surgery to death or follow-up during the period in question.

Data Collection and Analysis
Data on the following preoperative variables were retrospectively analyzed: age, sex, hepatitis B virus antigen, anti-hepatitis C virus, indocyanine green retention 15 minutes after administration (ICG-R15), gamma-glutamyl transferase (GGT), carbohydrate antigen 19-9 (CA 19-9), AFP, and DCP. In addition, tumor size and the postoperative pathological variables of histological differentiation, fibrovascular infiltration, MVI (including cases of portal vein invasion or hepatic vein invasion), bile duct invasion, intrahepatic metastasis, liver cirrhosis, and TNM Classification of Malignant Tumors (TNM) stage were also examined (Table 1).

Statistical analysis was performed with the statistical software package SPSS version 22.0 for Windows (SPSS, Chicago, IL). Continuous variables were expressed as the median (range) and compared between groups using the Wilcoxon rank-sum test. Categorical data were compared using the χ² test. Survival curves were generated by the Kaplan–Meier method and compared using a log-rank test. Multivariate regression analysis was performed with the Cox proportional hazards regression model using a backward elimination procedure in order to identify risk factors affecting postoperative survival and tumor recurrence. To prevent overfitting, only factors that were significantly associated with postoperative survival or tumor recurrence (with P < 0.05 according to univariate comparison) were included in the multivariate analysis. Results of the multivariate analysis are presented as hazard ratio (HR) with a corresponding 95% confidence interval (CI). All statistical tests were 2 sided, and P < 0.05 was considered to indicate a significant difference.

RESULTS
Baseline Characteristics
In total, 384 patients with single primary HCC who underwent curative hepatic resection (305 male patients and 79 female patients) and who had a median age of 65 years (range: 19–85 years) were studied (Table 1). With a median follow-up of 57.5 months (range: 1–174.5 months), 253 patients (65.9%) had recurrence of HCC and 108 patients (28.1%) died. The 1-, 3-, and 5-year survival rates were 96.4%, 83.5%, and 68.9%, and the 1-, 3-, and 5-year RFS rates were 72.8%, 43.3%, and 27.0%, respectively. The overall survival rate and overall RFS rate was 71.9% and 34.1%, respectively.

| Variables | Patients | % |
|-----------|----------|---|
| Age (> 60y) | 246 | 64.1 |
| Sex (male) | 305 | 79.4 |
| HBsAg (positive) | 89 | 23.2 |
| Anti-HCV (positive) | 221 | 57.6 |
| ICG-R15 (>0%) | 231 | 64.7 |
| GGT<sup>1</sup> | Median value of 61 U/L (range: 9-816 U/L) | |
| > 50 U/L | 237 | 62.0 |
| > 60 U/L | 194 | 50.8 |
| > 80 U/L | 159 | 41.6 |
| > 100 U/L | 99 | 25.9 |
| CA 19-9 (>37 U/mL)<sup>2</sup> | 92 | 25.6 |
| AFP (>10 ng/mL) | 220 | 57.3 |
| AFP (>400 ng/mL) | 70 | 18.2 |
| DCP (>400 AU/mL) | 208 | 54.2 |
| DCP (>100 AU/mL) | 150 | 39.1 |
| Tumor size | Median value of 3.5 cm (range: 0.7–22.0 cm) | |
| Tumor < 3.0 cm | 149 | 38.8 |
| Tumor < 5.0 cm | 248 | 64.6 |
| 5 cm ≤ tumor < 10 cm | 108 | 28.1 |
| Tumor ≥ 10 cm | 28 | 7.3 |
| Histological differentiation | | |
| Well | 98 | 25.5 |
| Moderate | 203 | 52.9 |
| Poor | 83 | 21.6 |
| Fibro capsular infiltration (present) | 204 | 53.1 |
| MVI (present) | 123 | 32.0 |
| Bile duct invasion (present) | 25 | 6.5 |
| Intrahepatic metastasis (present) | 55 | 14.3 |
| Liver cirrhosis (present) | 185 | 48.2 |
| TNM | | |
| Stage I | 59 | 15.4 |
| Stage II | 211 | 54.9 |
| Stage III | 114 | 29.7 |
| Survival time (median, range), mo | 58 (1–192) | |
| Recurrence-free survival (median, range), mo | 27 (1–175) | |

AFP = alpha-fetoprotein, Anti-HCV = anti-hepatitis C virus, CA 19-9 = carbohydrate antigen 19-9, DCP = des-gamma-carboxy-prothrombin, GGT = gamma-glutamyl transferase, ICG-R15 = indocyanine green retention 15 min, HBsAg = hepatitis B virus antigen, HCC = hepatocellular carcinoma, MVI = microvascular invasion, TNM = TNM Classification of Malignant Tumors (TNM).

<sup>1</sup> GGT was measured in 382 patients.
<sup>2</sup> GGT was measured in 357 patients.
<sup>3</sup> CA 19-9 was measured in 359 patients.

Risk Factors Affecting 1-, 3-, and 5-Year Survival Postoperatively
To identify risk factors affecting 1-, 3-, and 5-year survival postoperatively, all selected preoperative variables and postoperative pathological variables listed in Table 1 were included in univariate analysis. Items with P < 0.05 in univariate analysis were selected as variables for inclusion in multivariate regression analysis using the Cox proportional hazard model. As shown in Table 2, GGT > 100 U/L was a statistically significant independent risk factor affecting 1-, 3-, and 5-year survival, whereas high levels of AFP, DCP, and CA 19-9 were statistically significant independent risk factors affecting 1-, 3-, and 5-year survival, respectively. Patients with MVI had a poorer prognosis over time.
### TABLE 2. Risk Factor Analysis of the 1-, 3-, and 5-y Survival for 384 Patients With Single Primary HCC After Hepatic Resection

| Variables                      | 1-y Survival, % | 3-y Survival, % | 5-y Survival, % |
|--------------------------------|-----------------|-----------------|-----------------|
|                                | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis |
| Death                          |                 |                 |                 |                 |                 |                 |
| (n = 13)                       |                 |                 |                 |                 |                 |                 |
| Survival                       | 7 (53.8)        | 81 (23.0)       | 0.018           | 3.072           | 0.046           | 23 (40.4)        | 58 (20.1)       | 0.002           | 1.941           | 0.019           | 32 (39.0)        | 31 (17.0)       | < 0.001         | 1.774           | 0.022           |
|                                | (1.022–9.231)   |                 |                 | (1.117–3.374)   |                 | (1.086–2.897)    |                 |                 | (1.868)         | 0.009           | (1.166–2.994)    |                 |                 |                 |
| CA 19-9 > 37 U/mL               | —               | —               | —               | —               | —               | —               | —               | —               | —               | —               | —               | —               | —               | —               | —               |
|                                | 29 (38.7)       | 32 (18.8)       | 0.001           | 1.941           | 0.019           | 32 (39.0)        | 31 (17.0)       | < 0.001         | 1.774           | 0.022           | (1.086–2.897)    |                 |                 |                 | (1.166–2.994)    |                 |
| AFP > 400 ng/mL                 | 7 (53.8)        | 60 (17.0)       | 0.004           | 4.505           | 0.007           | 42 (73.7)        | 142 (49.1)      | 0.001           | 2.268           | 0.007           | —               | —               | —               | —               | —               |
|                                | (1.499–13.539)  |                 |                 | (1.246–4.127)   |                 | (1.086–2.897)    |                 |                 | (1.166–2.994)    |                 | —               | —               | —               | —               | —               |
| DCP > 40 mAU/mL                 | 52 (46.1)       | 241 (69.3)      | 0.039           | 1.432           | 0.037           | 241 (69.3)       | 241 (69.3)      | —               | —               | —               | —               | —               | —               | —               | —               |
|                                | (1.238–4.619)   |                 |                 | (1.210–4.656)   |                 | (1.238–4.619)    |                 |                 | (1.166–2.994)    |                 | —               | —               | —               | —               | —               |
| Tumor size ≥ 3cm               | 12 (92.3)       | 209 (59.2)      | 0.019           | 0.108           | 0.003           | 44 (77.2)        | 163 (56.4)      | 0.003           | 0.154           | 0.001           | 40 (48.8)        | 59 (32.4)       | 0.019           | 0.092           | —               |
|                                | (2.68–5.23)     |                 |                 | (2.30–5.20)     |                 | (2.68–5.23)      |                 |                 | (2.30–5.20)     |                 | (2.68–5.23)      |                 |                 |                 | —               |
| MVI (present)                  | 26 (45.6)       | 92 (31.8)       | 0.048           | 0.090           | 0.001           | 29 (50.9)        | 80 (27.7)       | 0.036           | 1.799           | 0.001           | 41 (50.0)        | 46 (25.3)       | < 0.001         | 2.098           | 0.002           |
|                                | (0.880–1.350)   |                 |                 | (0.864–1.084)   |                 | (0.880–1.350)    |                 |                 | (0.864–1.084)   |                 | (0.880–1.350)    |                 |                 |                 | (1.309–3.363)    |
| Intrahepatic metastasis (present)| —               | —               | —               | —               | —               | —               | —               | —               | —               | —               | —               | —               | —               | —               | —               |
|                                | 4 (7.0)         | 53 (18.3)       | 0.001           | 8.98            | (53.8)          | 36 (19.8)        | 36 (19.8)       | —               | —               | —               | —               | —               | —               | —               | —               |
| TNM                            |                 |                 |                 |                 |                 |                 |                 |                 |                 |                 |                 |                 |                 |                 |                 | —               |
| Stage I                        | —               | —               | —               | —               | —               | —               | —               | —               | —               | —               | —               | —               | —               | —               | —               |
| Stage II                       | —               | —               | —               | —               | —               | —               | —               | —               | —               | —               | —               | —               | —               | —               | —               |
| Stage III                      | —               | —               | —               | —               | —               | —               | —               | —               | —               | —               | —               | —               | —               | —               | —               |

**Notes:**
- AFP = alpha-fetoprotein, CA 19-9 = carbohydrate antigen 19-9, CI = confidence interval, DCP = des-gamma-carboxy-prothrombin, GGT = gamma-glutamyl transferase, HCC = hepatocellular carcinoma, HR = hazard ratio, MVI = microvascular invasion, TNM = TNM Classification of Malignant Tumors (TNM).
- 352 patients with GGT > 100 U/L survived 1 y, and 288 patients with GGT > 100 U/L survived 3 y.
- 245 patients with CA 19-9 > 37 U/ml at 5 y (75 patients died and 170 survived).
Patients with GGT > 100 U/L had a 1-, 3-, and 5-year survival rate of 92.0%, 71.6%, and 49.2%, respectively, and these rates significantly differed in comparison to patients with GGT ≤ 100 U/L, who had a 1-, 3-, and 5-year survival rate of 97.8%, 87.1%, and 75.0% (P < 0.05 for the 1-, 3-, and 5-year survival of the 2 groups) (Figure 1A).

In addition, GGT > 100 U/L was also identified as a statistically significant independent risk factor associated with overall survival (HR = 1.971, 95% CI = 1.296–2.997, P = 0.002). Patients with GGT > 100 U/L had an overall survival rate of 60.6%, which was poor than that in patients with GGT ≤ 100 U/L (75.6%) (P = 0.006).

Risk Factors Affecting 1-, 3-, and 5-Year RFS Postoperatively

The risk factors affecting 1-, 3-, and 5-year RFS postoperatively were also investigated using univariate analysis and multivariate analysis. As shown in Table 3, GGT > 50 U/L was a statistically significant independent risk factor affecting 1-, 3-, and 5-year RFS, whereas ICG-R15 > 10% was a statistically significant independent risk factor affecting 3- and 5-year RFS. In addition, GGT > 50 U/L (HR = 1.433, 95% CI = 1.092–1.881, P = 0.010) and ICG-R15 > 10% (HR = 1.627, 95% CI = 1.213–2.182, P = 0.001) were also identified as a statistically significant independent risk factor associated with overall RFS. In addition, the presence of MVI or intrahepatic metastasis was also identified as a risk factor associated with tumor recurrence.

Patients with GGT > 50 U/L had a 1-, 3-, and 5-year RFS rate of 64.5%, 36.0%, and 21.7%, respectively, and these rates significantly differed in comparison to patients with GGT ≤ 50 U/L, who had a 1-, 3-, and 5-year RFS rate of 86.3%, 54.7%, and 36.5%, respectively (P < 0.05 for the 1-, 3-, and 5-year RFS of the 2 groups) (Figure 1B). In addition, patients with GGT > 50 U/L had an overall RFS rate of 27.4%, which was lower than that in patients with GGT ≤ 50 U/L (44.1%) (P = 0.001).

Relationship Between GGT, ICG-R15, and RFS

As shown in Table 3, high levels of GGT and ICG-R15 preoperatively were identified as independent risk factors for postoperative recurrence. Of all 384 patients, 152 patients (42.6%) had GGT > 50 U/L and ICG-R15 > 10%, 160 (44.8%) had GGT > 50 U/L and ICG-R15 ≤ 10% or GGT ≤ 50 U/L and ICG-R15 > 10%, 45 (12.6%) had GGT ≤ 50 U/L and ICG-R15 ≤ 10%, and 27 were lost to follow-up.

As shown in Figure 2, patients with GGT > 50 U/L and ICG-R15 > 10% had a 1-, 3-, and 5-year RFS of 62.4%, 29.5%, and 14.1%, respectively. These patients had lower RFS rates than did patients in the other 2 groups with different levels of GGT and ICG (P < 0.05, respectively). In addition, all 384 patients, patients with GGT > 50 U/L and ICG-R15 > 10% had an overall RFS rate of 19.7%, which was lower than that in patients with GGT > 50 U/L and ICG-R15 ≤ 10% or GGT ≤ 50 U/L and ICG-R15 > 10% (overall RFS rate of 33.8%), and patients with GGT ≤ 50 U/L and ICG-R15 ≤ 10% (overall RFS rate of 53.3%) (P < 0.05, respectively).

Risk Factors Affecting 1-, 3-, and 5-Year RFS Postoperatively for Patients With a Tumor < 5 cm in Size

Numerous studies have reported that a large tumor is a factor influencing the recurrence of HCC. In the 384 patients in the present study, the median tumor size was 3.5 cm (range: 0.7–22.0 cm). One hundred thirty-six patients (35.4%) had a tumor > 5.0 cm in size. In order to exclude the influence of a larger tumor size and further investigate the relationship between clinicopathological variables and recurrence, 248 patients with tumor < 5 cm in size were further analyzed using univariate and multivariate analysis.

As shown in Table 4, multivariate regression analysis using the Cox proportional hazard model with backward elimination identified the following variables as independent risk factors: GGT > 50 U/L, ICG-R15 > 10%, and tumor size < 5 cm. Furthermore, the presence of MVI or intrahepatic metastasis was also identified as a risk factor affecting 1-, 3-, and 5-year RFS.
| Variables | 1-y RFS | 3-y RFS | 5-y RFS |
|-----------|---------|---------|---------|
|           | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis |
| Recurrence | Nonrecurrence | HR (95% CI) | P | Recurrence | Nonrecurrence | HR (95% CI) | P | Recurrence | Nonrecurrence | HR (95% CI) | P |
| ICG-R15 > 10%<sup>a</sup> | — | — | — | — | — | — | — | — | — | — | — | — |
| GGT > 50 U/L<sup>b</sup> | 82 (81.2) | 149 (55.4) | <0.001 | 2.119 | 0.004 | — | — | — | — | — | — | — |
| AFP > 400ng/mL | 28 (27.7) | 40 (14.8) | 0.006 | 0.293 | — | — | — | — | — | — | — | — |
| DCP > 40 mAU/mL | 68 (67.3) | 136 (50.4) | 0.005 | 0.404 | — | — | — | — | — | — | — | — |
| Tumor size ≥ 3 cm | 81 (80.2) | 144 (53.3) | <0.001 | 1.776 | 0.027 | — | — | — | — | — | — | — |
| Tumor size ≥ 5 cm | 54 (53.5) | 78 (28.9) | <0.001 | 0.493 | — | — | — | — | — | — | — | — |
| Histological differentiation | — | — | — | — | — | — | — | — | — | — | — | — |
| Well | — | — | — | — | — | — | — | — | — | — | — | — |
| Moderate | — | — | — | — | — | — | — | — | — | — | — | — |
| Poor | — | — | — | — | — | — | — | — | — | — | — | — |
| Fibrosascular infiltration (present) | 68 (67.3) | 131 (48.5) | 0.003 | 0.303 | — | — | — | — | — | — | — | — |
| MVI (present) | 59 (58.4) | 64 (23.7) | <0.001 | 2.138 | 0.001 | — | — | — | — | — | — | — |
| Intrahepatic metastasis (present) | 26 (25.7) | 27 (10.0) | <0.001 | 1.577 | 0.034 | — | — | — | — | — | — | — |
| Liver cirrhosis (present) | — | — | — | — | — | — | — | — | — | — | — | — |
| TNM<sup>c</sup> | — | — | <0.001 | — | — | — | — | — | — | — | — | — |
| Stage I | 5 (5.0) | 53 (19.6) | — | — | — | — | — | — | — | — | — | — |
| Stage II | 38 (37.6) | 161 (59.6) | — | — | — | — | — | — | — | — | — | — |
| Stage III | 58 (57.4) | 56 (20.7) | — | — | — | — | — | — | — | — | — | — |

AFP = alpha-fetoprotein, CI = confidence interval, DCP = des-gamma-carboxy-prothrombin, GGT = gamma-glutamyl transferase, HR = hazard ratio, HCC = hepatocellular carcinoma, ICG-R15 = indocyanine green retention 15 min, MVI = microvascular invasion, RFS = recurrence-free survival, TNM = TNM Classification of Malignant Tumors (TNM).

<sup>a</sup> 337 patients with ICG-R15 > 10% at 3 y (201 with recurrence and 136 with no recurrence), 301 patients with ICG-R15 > 10% at 5 y (229 with recurrence and 72 with no recurrence).

<sup>b</sup> 269 patients with GGT > 50 U/L and no recurrence at 1 y, and 155 patients with GGT > 50 U/L and no recurrence at 3 y.
factors affecting RFS in 248 patients with a tumor less than 5 cm in size: GGT > 50 U/L for 1- and 5-year RFS, ICG-R15 > 10% for 3- and 5-year RFS; a tumor ≥ 3.0 cm in size and the presence of intrahepatic metastasis for 1-year RFS, and the presence of liver cirrhosis for 5-year RFS.

**TABLE 4.** Univariate and Multivariate Analysis of Risk Factors Affecting the 1-, 3-, and 5-y RFS for 248 Patients With HCC < 5 cm in Size

| Variables | 1-y RFS | 3-y RFS | 5-y RFS |
|-----------|---------|---------|---------|
| Age > 60 y | Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate |
| P value | — | — | — | — | — | — |
| HR (95% CI) | — | — | — | — | — | — |
| ICG-R15 > 10% | — | — | — | — | — | — |
| P value | — | — | — | — | — | — |
| HR (95% CI) | — | — | — | — | — | — |
| GGT > 50 U/L | 0.001 | 0.010 | 0.023 | 0.059 | 0.046 | 0.031 |
| P value | — | — | — | — | — | — |
| CA 19-9 > 37 U/mL | 2.516 (1.244–5.091) | — | — | — | 1.464 (1.034–2.073) | — |
| 3 cm ≤ tumor size < 5 cm | 0.005 | 0.041 | — | — | — | — |
| P value | — | — | — | — | — | — |
| HR (95% CI) | — | 1.840 (1.026–3.299) | — | — | — | — |
| Histological differentiation | — | — | 0.048 | 0.421 | — | — |
| P value | — | — | — | — | — | — |
| HR (95% CI) | — | — | — | — | — | — |
| MVI (present) | 0.047 | 0.201 | — | — | — | — |
| P value | — | — | — | — | — | — |
| HR (95% CI) | — | — | — | — | — | — |
| Intrahepatic metastasis | 0.034 | 0.036 | — | — | — | — |
| P value | — | — | — | — | — | — |
| HR (95% CI) | 2.255 (1.053–4.829) | — | — | — | — | — |
| Liver cirrhosis (present) | 0.046 | 0.070 | — | — | — | — |
| P value | — | — | — | — | — | — |
| HR (95% CI) | — | — | — | — | — | — |
| TNM stage | 0.010 | — | — | — | — | — |

CA 19-9 = carbohydrate antigen 19-9, CI = confidence interval, GGT = gamma-glutamyl transferase, HCC = hepatocellular carcinoma, HR = hazard ratios, ICG-R15 = indocyanine green retention 15 min, MVI = microvascular invasion, RFS = recurrence-free survival, TNM = TNM Classification of Malignant Tumors (TNM)

**DISCUSSION**

Owing to the high rate of recurrence after hepatic resection, the risk factors for tumor recurrence must be ascertained. That information could help to take interventional measures earlier and facilitate better surveillance to reduce the rate of recurrence and improve the quality of care for patients with HCC. The present study examined the postoperative pathological variables of MVI and intrahepatic metastasis. Several studies have confirmed that MVI and intrahepatic metastasis are risk factors associated with an increased risk of recurrence and decreased survival. The present study yielded similar findings.
The present study focused on preoperative predictors of postoperative survival and recurrence in patients with single primary HCC who underwent hepatic resection. GGT > 100 U/L was identified as a preoperative independent risk factor associated with survival, and GGT > 50 U/L and ICG-R15 > 10% were identified as preoperative independent risk factors associated with tumor recurrence. Patients with GGT > 50 U/L and ICG-R15 > 10% had a worse 1-, 3-, and 5-year RFS, and this was also true for patients with a tumor < 5 cm in size. These results suggest that combined information in the form of high levels of GGT and ICG-R15 warrants full attention as a preoperative predictor associated with tumor recurrence for patients with single primary HCC undergoing hepatic resection.

GGT is an important enzyme catalyzing the hydrolysis of glutathione and the transfer of gamma-glutamyl residues, and GGT has been widely used as a marker enzyme for some neoplasms, such as lung tumors and ovarian tumors. GGT was investigated and selected as a liver function test or operative predictor associated with survival and tumor recurrence in patients with HCC. GGT > 50 U/L was identified as a preoperative independent risk factor affecting 1-, 3-, and 5-year RFS; GGT > 100 U/L was identified as a preoperative independent risk factor affecting 1-, 3-, and 5-year survival. These findings further confirm the role of GGT as a preoperative independent risk factor associated with survival and tumor recurrence in patients with HCC.

Findings from numerous studies have suggested 2 possible molecular mechanisms for the association between GGT and the recurrence of HCC and poor survival. One is that GGT may be associated with worse liver function via induction of DNA instability and subsequent onco genesis, whereas the other is that GGT may be associated with the degree of malignancy of HCC, such as vascular invasion, tumor metastasis, or a worse grade of tumor differentiation. GGT can facilitate DNA damage, genomic instability, and genetic mutation by increasing the uptake of iron, and iron has been identified as playing a role in carcinogenesis. This mechanism is thought to lead to the death of normal liver cells or the loss of normal liver function. GGT is reported to play a prooxidant role and the subsequent production of reactive oxygen species (ROS) may promote certain intra-cellular and extracellular molecular signals. ROS were reported to promote an epithelial-to-mesenchymal transition via the Snail-E-cadherin pathway and induce inflammation and invasion via the nuclear factor kappa B pathway. A study of U937 lymphoma cells found that GGT may play a role in antiapoptotic signaling. Another study confirmed that cysteinylglycine, which is catalyzed by GGT, is able to form complexes with cisplatin and that such adducts are not readily transported through the cell membrane. These mechanisms are thought to account for the progression of HCC, and the molecular mechanisms of the association between GGT and the recurrence of HCC and poor survival should be investigated further.

ICG-R15 is a common parameter for preoperative assessment of preserved hepatic function. ICG-R15 is reported to be an early indicator of hepatic dysfunction and it has been used preoperatively to plan the extent of partial hepatectomy by predicting the risk of dysfunction after surgery. ICG-R15 with a cutoff value of 10% as an upper limit of normal has been widely used in clinical practice in Japan. In the present study, ICG-R15 > 10% was identified as a preoperative independent risk factor affecting 3- and 5-year RFS. Furthermore, patients with GGT > 50 U/L and ICG-R15 > 10% had a worse 1-, 3-, and 5-year RFS, and the same was also true for patients with a tumor < 5 cm in size. These results suggest that combined information in the form of high levels of GGT and ICG-R15 could be a more convenient and accurate preoperative predictor with which to evaluate tumor recurrence postoperatively.

In conclusion, the present study identified the preoperative variables of GGT > 50 U/L and ICG-R15 > 10% as independent risk factors for tumor recurrence in patients with single
primary HCC who underwent hepatic resection. Patients with high levels of GGT and ICG-R15 had a worse 1-, 3-, and 5-year RFS, and the same was also true for patients with a tumor < 5 cm in size. Therefore, combined information in the form of high levels of GGT and ICG-R15 warrants full attention when evaluating tumor recurrence postoperatively. This information should help surgeons to take more effective interventional measures earlier in order to reduce recurrence and improve the quality of care for patients with HCC.

REFERENCES
1. Sharifi AR, Elarabi YE. The ‘watering-can’ perineum: presentation and management. Br J Urol. 1997;80:933–936.
2. Rahbari NN, Mehrabi A, Mollberg NM, et al. Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg. 2011;253:453–469.
3. Ardiles V, Sanchez Claría R, Mazza OM, et al. Prognostic factors after resection of hepatocellular carcinoma in the non-cirrhotic liver: presentation of 51 cases. Cir Esp. 2010;87:148–154.
4. Smoot RL, Nagorney DM, Chandan VS, et al. Resection of hepatocellular carcinoma in patients without cirrhosis. Br J Surg. 2011;98:697–703.
5. Verhoef C, de Man RA, Zondervan PE, et al. Good outcomes after resection of large hepatocellular carcinoma in the non-cirrhotic liver. Dig Surg. 2004;21:380–386.
6. Zhang W, Zhao G, Wei K, et al. Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: a single-center experience. Biosci Trends. 2014;8:333–338.
7. Gao JJ, Song PP, Tamura S, et al. Standardization of perioperative management on hepatobiliary-pancreatic surgery. Drug Discov Ther. 2012;6:108–111.
8. Poon RT, Fan ST, Lo CM, et al. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg. 2002;235:373–382.
9. Muscat F, Foppa B, Carrere N, et al. Resection of a transplantable single-nodule hepatocellular carcinoma in Child-Pugh class A cirrhosis: factors affecting survival and recurrence. World J Surg. 2011;35:1055–1062.
10. Zhu L, Rui JA, Wang SB, et al. Factors predictive for long-term survival of male patients with hepatocellular carcinoma after curative resection. J Surg Oncol. 2007;95:298–303.
11. Naito S, Imamura H, Tukada A, et al. Postoperative recurrence pattern and prognosis of patients with hepatocellular carcinoma, with particular reference to the hepatitis virus infection status. Liver Int. 2014;34:802–813.
12. Guo R, Feng X, Xiao S, et al. Short- and long-term outcomes of hepatectomy with or without radiofrequency-assist for the treatment of hepatocellular carcinomas: a retrospective comparative cohort study. Biosci Trends. 2015;9:65–72.
13. Zhu WJ, Huang CY, Li C, et al. Risk factors for early recurrence of HBV-related hepatocellular carcinoma meeting milan criteria after curative resection. Asian Pac J Cancer Prev. 2013;14:7101–7106.
14. Park SK, Jung YK, Chung DH, et al. Factors influencing hepatocellular carcinoma prognosis after hepatectomy: a single-center experience. Korean J Intern Med. 2013;28:428–438.
15. Lim KC, Chow PK, Allen JC, et al. Microvascular invasion is a better predictor of tumour recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg. 2011;254:108–113.
16. Hung HH, Lei HJ, Chau GY, et al. Milan criteria, multi-nodularity, and microvascular invasion predict the recurrence patterns of hepatocellular carcinoma after resection. J Gastrointest Surg. 2013;17:702–711.
17. Carr BI, Pancoska P, Branch RA. Low alpha-fetoprotein hepatocellular carcinoma. J Gastroenterol Hepatol. 2010;25:1543–1549.
18. Zhao WC, Zhang HB, Yang N, et al. Preoperative predictors of short-term survival after hepatectomy for multinodular hepatocellular carcinoma. World J Gastroenterol. 2012;18:3272–3281.
19. Faber W, Sharafi S, Stockmann M, et al. Long-term results of liver resection for hepatocellular carcinoma in noncirrhotic liver. Surgery. 2013;153:510–517.
20. Guu B, Deschamps F, Boulin M, et al. Serum gamma-glutamyltransferase independently predicts outcome after transarterial chemoembolization of hepatocellular carcinoma: external validation. Cardiovasc Intervent Radiol. 2012;35:1102–1108.
21. Nishikawa H, Nishijima N, Arimoto A, et al. Prognostic factors in patients with hepatitis B virus-related hepatocellular carcinoma undergoing nucleoside analog antiviral therapy. Oncol Lett. 2013;6:1213–1218.
22. Shindoh J, Hasegawa K, Matsuyama Y, et al. Low hepatitis C viral load predicts better long-term outcomes in patients undergoing resection of hepatocellular carcinoma irrespective of serologic eradication of hepatitis C virus. J Clin Oncol. 2013;31:766–773.
23. Shindoh J, Hasegawa K, Inoue Y, et al. Risk factors of postoperative recurrence and adequate surgical approach to improve long-term outcomes of hepatocellular carcinoma. HPB (Oxford). 2013;15:31–39.
24. Liver Cancer Study Group of Japan. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer. Tokyo: Kanehara-Syuppun; 2008.
25. Nagasue N, Ono T, Yamanoi A, et al. Prognostic factors and survival after hepatic resection for hepatocellular carcinoma without cirrhosis. Br J Surg. 2001;88:515–522.
26. Laurent C, Blanc JF, Nobili S, et al. Prognostic factors and long-term survival after hepatic resection for hepatocellular carcinoma originating from noncirrhotic liver. J Am Coll Surg. 2005;201:656–662.
27. Song P, Feng X, Inagaki Y, et al. Clinical utility of simultaneous measurement of alpha-fetoprotein and des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma in China: a multi-center case-controlled study of 1,153 subjects. Biosci Trends. 2014;8:266–273.
28. Song P, Feng X, Zhang K, et al. Perspectives on using des-gamma-carboxyprothrombin (DCP) as a serum biomarker: facilitating early detection of hepatocellular carcinoma in China. Hepatobiliary Surg Nutr. 2013;2:227–231.
29. Esnaola NF, Mirza N, Lauwers GY, et al. Comparison of clinicopathologic characteristics and outcomes after resection in patients with hepatocellular carcinoma treated in the United States, France, and Japan. Ann Surg. 2003;238:711–719.
30. Ikai I, Arii S, Kojio M, et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer. 2004;101:796–802.
31. Zeng QA, Qiu J, Hong J, et al. Hepatectomy for hepatocellular carcinoma patients with macronodular cirrhosis. Eur J Gastroenterol Hepatol. 2012;24:575–582.
32. Akamatsu N, Sugawara Y, Kokudo N. Acute liver failure and liver transplantation. Intractable Rare Dis Res. 2013;2:77–87.
33. Wetmore LA, Gerard C, Drazen JM. Human lung expresses unique mammalian transthyretin transcripts. Proc Natl Acad Sci USA. 1993;90:7461–7465.
34. Hanigan MH, Frierson HF Jr, Brown JE, et al. Human ovarian tumors express gamma-glutamyl transpeptidase. Cancer Res. 1994;54:286–290.
35. Hudson EA, Munks RJ, Manson MM. Characterization of transcriptional regulation of gamma-glutamyl transpeptidase in rat liver involving both positive and negative regulatory elements. Mol Carcinog. 1997;20:376–388.
36. Brouillet A, Holic N, Chobert MN, et al. The gamma-glutamyl transpeptidase gene is transcribed from a different promoter in rat hepatocytes and biliary cells. Am J Pathol. 1998;152:1039–1048.
37. Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci. 2001;38:263–355.
38. Tsutsumi M, Sakamuro D, Takada A, et al. Detection of a unique gamma-glutamyl transpeptidase messenger RNA species closely related to the development of hepatocellular carcinoma in humans: a new candidate for early diagnosis of hepatocellular carcinoma. Hepatology. 1996;23:1093–1097.
39. Goldberg DM, Martin JV. Role of gamma-glutamyl transpeptidase activity in the diagnosis of hepatobiliary disease. Digestion. 1975;12:232–246.
40. Ellis G, Worthy E, Goldberg DM. Lack of value of serum gamma-glutamyl transferase in the diagnosis of hepatobiliary disease. Clin Biochem. 1979;12:142–145.
41. Ruppen DC, Frydman MJ, Lunzer MR. Value of serum gamma-glutamyltransferase activity in the diagnosis of hepatobiliary disease. Med J Aust. 1982;1:421–424.
42. Sheen IS, Jeng KS, Tsai YC. Is the expression of gamma-glutamyl transpeptidase messenger RNA an indicator of biological behavior in recurrent hepatocellular carcinoma? World J Gastroenterol. 2003;9:468–473.
43. Ju MJ, Qiu SJ, Fan J, et al. Preoperative serum gamma-glutamyl transferase to alanine aminotransferase ratio is a convenient prognostic marker for Child-Pugh A hepatocellular carcinoma after operation. J Gastroenterol. 2009;44:635–642.
44. Zhao WC, Fan LF, Yang N, et al. Preoperative predictors of microvascular invasion in multinodular hepatocellular carcinoma. Eur J Surg Oncol. 2013;39:858–864.
45. Zhang JB, Chen Y, Zhang B, et al. Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Eur J Gastroenterol Hepatol. 2011;23:787–793.
46. Wang Z, Song P, Xia J, et al. Can gamma-glutamyl transferase levels contribute to a better prognosis for patients with hepatocellular carcinoma? Drug Discov Ther. 2014;8:134–138.
47. Corti A, Duarte TL, Giommarelli C, et al. Membrane gamma-glutamyl transferase activity promotes iron-dependent oxidative DNA damage in melanoma cells. Mutat Res. 2009;669:112–121.
48. Weinberg ED. The role of iron in cancer. Eur J Cancer Prev. 1996;5:19–36.
49. Stark AA, Russell JJ, Langenbach R, et al. Localization of oxidative damage by a glutathione-gamma-glutamyl transpeptidase system in preneoplastic lesions in sections of livers from carcinogen-treated rats. Carcinogenesis. 1994;15:343–348.
50. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3’ kinase/ Akt pathways. Oncogene. 2005;24:7443–7454.
51. Javed S, Mejias-Luque R, Kalali B, et al. Helicobacter bilis gamma-glutamyltransferase enhances inflammatory stress response via oxidative stress in colon epithelial cells. PLoS One. 2013;8:e73160.
52. Wu Y, Zhou BP. TNF-alpha/NF-kappaB/Stat6 pathway in cancer cell migration and invasion. Br J Cancer. 2010;102:639–644.
53. Moon DO, Kim BY, Jang JH, et al. K-RAS transformation in prostate epithelial cell overrides H2O2-induced apoptosis via upregulation of gamma-glutamyltransferase-2. Toxicol In Vitro. 2012;26:429–434.
54. Paolucci A, Sotiropoulou M, Perego P, et al. gamma-Glutamyl transpeptidase catalyses the extracellular detoxification of cisplatin in a human cell line derived from the proximal convoluted tubule of the kidney. Eur J Cancer. 2003;39:996–1003.
55. Kim HJ, Kim CY, Park EK, et al. Volumetric analysis and indocyanine green retention rate at 15 min as predictors of post-hepatectomy liver failure. HPB (Oxford). 2015;17:159–167.
56. Lisotti A, Azzaroli F, Buonfiglioli F, et al. Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis. Hepatology. 2014;59:643–650.
57. Fung J, Poon RT, Yu WC, et al. Use of liver stiffness measurement for liver resection surgery: correlation with indocyanine green clearance testing and post-operative outcome. PLoS One. 2013;8:e27306.
58. Zipprich A, Kuss O, Rogowski S, et al. Incorporating indocyanin green clearance into the Model for End Stage Liver Disease (MELD-ICG) improves prognostic accuracy in intermediate to advanced cirrhosis. Gut. 2010;59:963–968.
59. Okabe H, Beppu T, Hayashi H, et al. Rank classification based on oxidative stress in colon hepatocytes and biliary cells. Proc Jpn Acad. 2013;89:95–100.
60. Okabe H, Seyama Y, Kokudo N. Assessment of liver function for the combination of indocyanine green retention rate at 15 min and the model for end-stage liver disease for the combination of indocyanine green retention rate at 15 min and the model for end-stage liver disease-ICG (MELD-ICG) improves prognostic accuracy in intermediate to advanced cirrhosis. Gut. 2010;59:963–968.
61. Akita H, Sasaki Y, Yamada T, et al. Real-time intraoperative assessment of residual liver functional reserve using pulse dye densitometry. World J Surg. 2008;32:2668–2674.